[Congressional Bills 114th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3537 Introduced in House (IH)]
<DOC>
114th CONGRESS
1st Session
H. R. 3537
To amend the Controlled Substances Act to clarify how controlled
substance analogues are to be regulated, and for other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
September 17, 2015
Mr. Dent (for himself, Mr. Himes, Mr. Meehan, Mr. Dold, Mr. Tiberi, Mr.
Costello of Pennsylvania, Mr. Hanna, Mr. Thompson of Pennsylvania, Mr.
Rogers of Kentucky, Mr. Murphy of Pennsylvania, Mr. Barletta, Ms.
Norton, Mr. Lance, Mrs. Comstock, Mr. Katko, Ms. Ros-Lehtinen, and Mr.
Jolly) introduced the following bill; which was referred to the
Committee on Energy and Commerce, and in addition to the Committee on
the Judiciary, for a period to be subsequently determined by the
Speaker, in each case for consideration of such provisions as fall
within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend the Controlled Substances Act to clarify how controlled
substance analogues are to be regulated, and for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Synthetic Drug Control Act of
2015''.
SEC. 2. CONTROLLED SUBSTANCE ANALOGUES.
(a) Expansion of Definition.--
(1) In general.--Clauses (i), (ii), and (iii) of section
102(32)(A) of the Controlled Substances Act (21 U.S.C.
802(32)(A)) are amended by striking ``substantially'' each
place it appears.
(2) Rule of construction.--Section 102(32)(A) of the
Controlled Substances Act (21 U.S.C. 82(32)(A)) shall not be
construed to require that a substance satisfy more than one of
the clauses listed in such section 102(32)(A) to meet the
definition of a controlled substance analogue.
(b) Limitation on Treatment as Controlled Substances.--Section 203
of the Controlled Substances Act (21 U.S.C. 813) is amended by
inserting before the period at the end the following: ``for purposes of
prohibitions, restrictions, and other requirements with respect to
manufacture, importation, distribution, and sale''.
SEC. 3. TREATMENT OF CERTAIN DESIGNER DRUGS AS SCHEDULE I CONTROLLED
SUBSTANCES.
(a) In General.--Schedule I, as set forth in section 202(c) of the
Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding at
the end the following:
``(e)(1) Unless specifically exempted or unless listed in another
schedule, any material, compound, mixture, or preparation which
contains any quantity of a substances listed in paragraphs (2) through
(10), or which contains the salts, isomers, and salts of isomers
thereof whenever the existence of such salts, isomers, and salts of
isomers is possible within the specific chemical designation.
``(2) Phenylalkylamines.--The substances listed in this paragraph
consist of the following phenylalkylamines:
``(A) 2-(ethylamino)-1-(4-methylphenyl)-1-propanone.
``(B) 1-(4-ethylphenyl)-2-(methylamino)-1-propanone.
``(C) 1-(3-fluorophenyl)-2-(methylamino)-1-propanone.
``(D) 1-(4-fluorophenyl)-2-(methylamino)-1-propanone.
``(E) 1-(4-methoxyphenyl)-2-(methylamino)-1-propanone.
``(F) 2-(ethylamino)-1-(4-methoxyphenyl)-1-propanone.
``(G) 1-(2-naphthalenyl)-2-(1-pyrrolidinyl)-1-pentanone.
``(H) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-propanone.
``(I) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-butanone.
``(J) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-pentanone.
``(K) 2-(ethylamino)-1-phenyl-1-propanone.
``(L) 1-phenyl-2-(1-pyrrolidinyl)-1-propanone.
``(M) 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-propanone.
``(N) 1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-1-propanone.
``(O) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-
propanone.
``(P) 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone.
``(Q) 2-amino-1-(4-fluoro)-1-propanone.
``(R) 2-(methylamino)-1-phenyl-1-pentanone.
``(S) 2-(ethylamino)-1-(4-ethylphenyl)-1-propanone.
``(T) 2-(dimethylamino)-1-phenyl-1-propanone.
``(U) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-
butanone.
``(V) 1-(methylphenyl)-2-(1-pyrrolidinyl)-1-hexanone.
``(W) 2-(methylamino)-1-phenyl-1-butanone.
``(X) 2-(methylamino)-1-p-tolyl-1-butanone.
``(Y) 1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-butanone.
``(Z) 1-(3,4-dimethylphenyl)-2-(methylamino)-1-propanone.
``(AA) 1-phenyl-2-(1-pyrrolidinyl)-1-butanone.
``(BB) 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-
propanone.
``(CC) 1-(4-methylphenyl)-2-(benzylamino)-1-propanone.
``(DD) 1-(1-naphthy)-2-(1-pyrrolidinyl)-1-pentanone.
``(EE) 1-(1,3-benzodioxol-5-yl)-2-(benzylamino)-1-
propanone.
``(FF) 1-(1,3-benzodioxol-5-yl)-2-(benzylamino)-1-butanone.
``(GG) 1-(1,3-benzodioxol)-2-[hydroxy(methyl)-amino]-1-
propanone.
``(HH) 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-
butanone.
``(II) 2-(ethyl(methyl)amino)-1-phenyl-butanone.
``(JJ) 1-(4-bromophenyl)-2-(methylamino)-1-propanone.
``(KK) 2-(ethyl(methyl)amino-1-phenyl-1-propanone.
``(LL) 2-(methylamino)-1-m-tolyl-1-propanone.
``(MM) 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)-1-pentanone.
``(NN) 1-(4-fluorophenyl)-2-(methylamino)-1-butanone.
``(OO) 1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)-1-butanone.
``(PP) 1-(4-ethylphenyl)-2-(pyrrolidin-1-yl)-1-butanone.
``(QQ) 1-(4-methoxy-3-methylphenyl)-2-(methylamino)-1-
propanone.
``(RR) 2-(ethylamino)-1-(3-methylphenyl)-1-propanone.
``(SS) 2-amino-(1H-indol-5-yl)propan-1-one.
``(TT) 1-phenyl-2-(piperidin-1-yl)butan-1-one.
``(UU) 2-methylamino-1-(2,4,5-trimethylphenyl)-propan-1-
one).
``(VV) 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one.
``(WW) 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one.
``(XX) 1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one.
``(YY) 1-(benzo[d][1,3]dioxol-5-yl)-2-
(dimethylamino)pentan-1-one.
``(ZZ) 1-(2-fluorophenyl)-N-methyl-propan-2-amine.
``(AAA) 1-(2-fluorophenyl)-propan-2-amine.
``(BBB) 1-(3-fluorophenyl)- propan-2-amine.
``(CCC) 1-(3-fluorophenyl)-N-methyl-propan-2-amine.
``(DDD) 1-(4-fluorophenyl)- propan-2-amine.
``(EEE) 1-(4-fluorophenyl)-N-methyl-propan-2-amine.
``(FFF) 1-(4-methylphenyl)propan-2-amine.
``(GGG) N-ethyl-N-methyl-1-phenylpropan-2-amine.
``(HHH) 1-(benzofuran-4-yl)propan-2-amine.
``(III) 1-(benzofuran-5-yl) propan-2-amine.
``(JJJ) 1-(2,3-dihydrobenzofuran-5-yl)proan-2-amine.
``(KKK) 1-(benzofuran-6-yl)- propan-2-amine.
``(LLL) 1-(2,3-dihydrobenzofuran-6-yl)proan-2-amine.
``(MMM) 1-(4-methoxyphenyl)-N-methyl-propan-2-amine.
``(NNN) N,N-dimethyl-1-phenylpropan-2-amine.
``(OOO) 1-(2,3-dihydro-1H-inden-5-yl)propan-2-amine.
``(PPP) 5,6,7,8-tetrahydrobenzo[1,3]-benzodioxol-7-amine.
``(QQQ) a-methyl-4-(methylthio)-benzene-ethanamine.
``(RRR) 1-(4-chlorophenyl)-propan-2-amine.
``(SSS) 1-(2,4,6-trimethoxyphenyl)-propan-2-amine.
``(TTT) 1-(2,4,5-trimethoxyphenyl)-propan-2-amine.
``(UUU) 1-(2,5-dimethylphenyl)-propan-2-amine.
``(VVV) 1-(3,4-dimethylphenyl)-propan-2-amine.
``(WWW) N-(1-phenylpropan-2-yl)propan-1-amine.
``(XXX) 4-(2-aminopropyl)phenol.
``(YYY) 3,4-methylenedioxy-N,N-dimethyl-amphetamine.
``(ZZZ) N-ethyl-1-(4-methoxyphenyl)propan-2-amine.
``(AAAA) 1-(benzofuran-5-yl)-N-methylpropan-2-amine.
``(BBBB) 6,7-dihydro-5H-inden[5,6-d][1,3]dioxol-6-amine.
``(CCCC) 5-iodo-2,3-dihydro-1H-inden-2-amine.
``(DDDD) 2,3-dihydro-1H-inden-2-amine.
``(EEEE) 5-methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine.
``(FFFF) N-methyl-6,7-dihydro-5H-cyclopenta[1,3]-
benzodioxol-6-amine.
``(GGGG) N-methyl-2,3-dihydro-1H-inden-2-amine.
``(HHHH) 2-[4-(2-fluoroethylthio)-2,5-
dimethoxyphenyl]ethanamine.
``(IIII) 8-bromo-2,3,6,7-tetrahydro-benzo[1,2-b;4,5-
b']difuran-4-ethanamine.
``(JJJJ) 4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)-methyl-
benzene-ethamine.
``(KKKK) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)-ethanamine.
``(LLLL) 2-(2,5-dimethoxy-3,4-dimethylphenyl)-ethanamine.
``(MMMM) 2-(4-methyl-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)-ethanamine.
``(NNNN) 2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)-ethanamine.
``(OOOO) 2-(2,5-dimethoxy-3,4-dimethylphenyl)-N-(2-
methoxybenzyl)-ethanamine.
``(PPPP) 2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)-
ethanamine.
``(QQQQ) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)-ethanamine.
``(RRRR) 2-(2,5-dimethoxyphenyl-4-nitro)-N-[(2-
methoxyphenyl)methyl]-ethanamine.
``(SSSS) 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine.
``(TTTT) 1-(4-bromofuro[2,3-f]benzofuran-8-yl)propan-2-
amine.
``(UUUU) 1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine.
``(VVVV) 1-(4-bromo-2,3,6,7-terahydrofuro[2,3-f]benzofuran-
8-yl)propan-2-amine.
``(WWWW) (2,5-dimethoxyphenyl)-propan-2-amine.
``(XXXX) 1-[4-(ethylthio)-2,5-dimethoxyphenyl)propan-2-
amine.
``(YYYY) 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine.
``(ZZZZ) 1-[2,5-dimethoxy-4-(propylthio)phenyl]propan-2-
amine.
``(AAAAA) 1-(4-ethyl-2,5-dimethoxyphenyl)propan-2-amine.
``(BBBBB) N-benzyl-2-phenylethanamine.
``(CCCCC) N,N-dimethyl-2-phenylethanamine.
``(DDDDD) 6-chloro-aminotetralin.
``(EEEEE) 2-phenyl-propan-1-amine.
``(FFFFF) 2-phenethylamine.
``(GGGGG) 1-methylamino-1-(3,4-methylendioxy-
phenyl)propane.
``(HHHHH) N-methyl-3-phenylbicyclo[2.2.1]heptan-2-amine.
``(IIIII) 1-(2-methoxyphenyl)-N-methylpropan-2-amine.
``(JJJJJ) 2-(4-(allyloxy)-3,5-dimethoxyphenyl)ethanamine.
``(KKKKK) 4-methylhexan-2-amine.
``(LLLLL) 4-methyl-5-phenyl-2-amino-oxazoline.
``(MMMMM) N-methyl-1-thiophen-2-yl)propan-2-amine.
``(NNNNN) (3-dimethylamino-2,2-dimethylpropyl)-4-
aminobenzoate.
``(OOOOO) 1-(4-fluorophenyl)-2-(methylamino)-propan-1-ol.
``(PPPPP) 4-methyl-5-p-tolyl-4,5-dihydrooxazol-2-amine.
``(QQQQQ) 1-phenyl-2-(pyrrolidin-1-yl)propan-1-ol.
``(3) Cannabimimetic Agents.--The substances listed in this
paragraph consist of the following cannabimimetic agents:
``(A) (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-
yl)methanone.
``(B) 2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)-
ethanone.
``(C) 1-[1-(2-cyclohexylethyl)-1H-indol-3-yl]-2-(2-
methoxyphenyl)-ethanone.
``(D) [1-(5-fluoropentyl)-1H-indol-3-yl](2-
iodophenyl)methanone.
``(E) (2-methyl-1-[(1-methylpiperidin-2-yl)methyl]-6-nitro-
1H-indol-3-yl)methanone.
``(F) (1-butyl-1H-indol-3-yl)(4-methoxyphenyl)-methanone.
``(G) (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-
yl)methanone.
``(H) [1-(5-fluoropentyl)-1H-indol-3-yl](4-methyl-1-
naphthalenyl)-methanone.
``(I) [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-1-
naphthalenyl-methanone.
``(J) 3-(4-methoxyphenyl)-2-methyl-1-[(2-(4-
morpholinyl)ethyl)-1H-indol-3-yl]-methanone.
``(K) [2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
naphthalenyl- methanone.
``(L) 2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-
ethanone.
``(M) (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-
indol-3-yl]-methanone.
``(N) [1-[(1-methyl-2-piperdinyl)methyl]-1H-indol-3-
yl]tricycle[3.3.1.13,7]dec-1-yl-methanone.
``(O) 1-naphthalenyl(1-propyl-1H-indol-3-yl)-methanone.
``(P) 5-[3-(1-naphthoyl)-1H-indole-1-yl]pentanenitrile.
``(Q) 3-(1-naphthenylmethyl)-1-pentyl-1H-indole.
``(R) (2-methyl-1-propyl-1H-indol-3-yl)-1-napthalenyl-
methanone.
``(S) 1-naphthalenyl[1-(4-penten-1-yl)-1H-indol-3-yl]-
methanone.
``(T) (4-bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone.
``(U) (4-fluoronaphthalen-1-yl)(1-pentyl-1H-indol-3-
yl)methanone.
``(V) (2-methyl-1-phenyl-1H-indol-3-yl)-1-naphthalenyl-
methanone.
``(W) 2-(2-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)-
ethanone.
``(X) [1-(5-chloropentyl)-1H-indol-3-yl](2-iodophenyl)-
methanone.
``(Y) (adamantan-1-yl)(1-pentyl-1H-indol-3-yl)-methanone.
``(Z) (2-iodo-5-nitrophenyl)-[1-(1-methylpiperidin-2-
ylmethyl)-1H-indol-3-yl]-methanone.
``(AA) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclo-
propyl)methanone.
``(BB) [1-(5-fluoropentyl-1H-indol-3-yl)](2,2,3,3-
tetramethylcyclo-propyl)methanone.
``(CC) [1-(2-morpholinoethyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone.
``(DD) 1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl-
(2,2,3,3-tetramethylcyclopropyl)methanone.
``(EE) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-
carboxamide.
``(FF) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-
3-carboxamide.
``(GG) 1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-
1H-indole-3-carboxamide.
``(HH) [1-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone.
``(II) (1-isopentyl-1H-indol-3-yl)(naphthalen-1-
yl)methanone.
``(JJ) 1-(5-fluoropentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-
indazole-3-carboxamide.
``(KK) (1-pentyl-1H-indol-3-yl)(4-propyl-1-naphthalenyl)-
methanone.
``(LL) [1-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone.
``(MM) (4-methyl-naphthalen-1-yl)[1-(pent-4-en-1-yl)-1H-
indol-3-yl]methanone.
``(NN) (2-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-
yl)methanone.
``(OO) (3-methoxy-phenyl)(1-pentyl-1H-indol-3-yl)methanone.
``(PP) [1-(5-fluoropentyl)-1H-indol-3-yl](4-ethyl-1-
naphthalenyl)-methanone.
``(QQ) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate.
``(RR) quinolin-8-yl 1-(5-fluoropentyl-1H-indole-3-
carboxylate.
``(SS) 1-(cyclohexylmethyl)-8-quinolinyl-ester-1H-indole-3-
carboxylic acid.
``(TT) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
indazole-3-carboxamide.
``(UU) 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-
carboxamide.
``(VV) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide.
``(WW) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-
fluorobenzyl)-1H-indazole-3-carboxamide.
``(XX) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-
1H-indole-3-carboxamide.
``(YY) 2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone.
``(ZZ) [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-
naphthalenyl-methanone.
``(AAA) 1-pentyl-N-(naphthalene-1-yl)-1H-indole-3-
carboxamide.
``(BBB) 1-(5-chloropentyl)-1H-indol-3-yl](4-methyl-1-
naphthalenyl)-methanone.
``(CCC) (4-methyl-naphthalen-1-yl)[2-methyl-1-(pent-4-en-1-
yl)-1H-indol-3-yl)]methanone.
``(DDD) [1-(5-fluoropentyl)-1H-indol-3-yl](o-
tolyl)methanone.
``(EEE) (2-ethylphenyl)(1-(5-fluoropentyl)-1H-indol-3-
yl)methanone.
``(FFF) [1-(5-chloropentyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone.
``(GGG) [1-(5-bromopentyl)-1H-indol-3-yl](naphthalen-1-
yl)methanone.
``(HHH) (1-(5-fluoropentyl)-1H-indazol-3-yl)(naphthalene-1-
yl)methanone.
``(III) 1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-
yl](2,2,3,3-tetramethylcyclopropyl)methanone.
``(JJJ) (1-(1-methylazepan-2-yl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone.
``(KKK) 4-hydroxy-3,3,4-trimethyl-1-(1-pentyl-1H-indol-3-
yl)pentan-1-one.
``(LLL) [1-(4-fluoropentyl)-1H-indol-3-yl]-1-naphthenyl-
methanone.
``(MMM) 2-(2-iodophenyl)-1-(1-pentyl-1H-indol-3-
yl)ethanone.
``(NNN) (1-hexyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone.
``(OOO) (2,2,3,3-tetramethylcyclopropyl)[1-(4,4,4-
trifluorobutyl)-1H-indol-3-yl]methanone.
``(PPP) 7-methoxy-1-(2-morpholinoethyl)-N-((1S,4R)-1,3,3-
trimethylbicyclo[2.2.1]heptan-2-yl)-1H-indole-3-ca rboxamide.
``(QQQ) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-
carboxylate.
``(RRR) naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-
carboxylate.
``(SSS) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-
1H-indazole-3-carboxamide.
``(TTT) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-carboxamide.
``(UUU) (1-(4-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone.
``(VVV) 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)methanone.
``(WWW) N-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide.
``(XXX) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexyl
methyl)-1H-indazole-3-carboxamide.
``(YYY) naphthalene-1-yl(9-pentyl-9H-carbazol-3-
yl)methanone.
``(ZZZ) naphthalene-1-yl 1-(5-fluoropentyl)-1H-indole-3-
carboxylate.
``(AAAA) methyl 3-methyl-2-(1-pentyl-1H-indazole-3-
carboxamido.
``(BBBB) methyl 2-(1-5-fluoropentyl)-1H-indazole-3-
caboxamido)-3-methylbutanoate.
``(CCCC) N-benzyl-1-pentyl-1H-indole-3-carboxamide.
``(DDDD) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-
carboxamide.
``(EEEE) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-
carboxamido)-3-methylbutanoate.
``(FFFF) quinolin-8-yl 1-pentyl-1H-indazole-3-carboxylate.
``(GGGG) quinolin-8-yl 1-(5-fluoropentyl)-1H-indazole-3-
carboxylate.
``(HHHH) naphthalene-2-yl 1-(2-fluorophenyl)-1H-indazole-3-
carboxylate.
``(IIII) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
(cyclohexylmethyl)-1H-indazole-3-carboxamide.
``(JJJJ) (1-(4-flourobenzyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone.
``(KKKK) N-(1-amino-1-oxo--3-phenylpropan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-carboxamide.
``(LLLL) N-(1-amino-1-oxo--3-phenylpropan-2-yl)-1-(5-
fluoropentyl)-1H-indazole-3-carboxamide.
``(MMMM) methyl (1-(cyclohexylmethyl)-1H-indazole-3-
carbonyl-L-valinate.
``(NNNN) N-[(1-(cyclohexylmethyl)-1H-indazole-
3yl)carbonyl]-3-methyl-L-valine, methyl ester.
``(OOOO) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-
carboxamido)-3,3-dimethylbutanoate.
``(PPPP) (1-(5-fluoropentyl)-1H-benzo[d]imidazole-2-
yl)(naphthalene-1-yl)methanone.
``(QQQQ) (1-(4-fluorobenzyl)-1H-indol-3-yl)(napthalen-1-
yl)methanone.
``(RRRR) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-
carboxamido)-3,3-dimethylbutanoate.
``(SSSS) quinolin-8-yl 1-(4-fluorobenzyl)-1H-indazole-3-
carboxylate.
``(TTTT) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-
3-carboxamide.
``(UUUU) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-1H-indole-3-carboxamide.
``(VVVV) 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methylheptyl-
2-yl)phenol.
``(WWWW) 2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-
methyldodecanyl-2-yl)phenol.
``(XXXX) 3-hydroxy-2[3-methyl-6-(1-methylethyenyl)-2-
cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione.
``(YYYY) 4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-
6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol.
``(ZZZZ) 1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-
methanone.
``(AAAAA) 3-(2-(hydroxymethyl)-2,3-dihydro-1H-inden-4-
yloxy)phenyl 4,4,4-trifluorobutane-1-sulfonate.
``(BBBBB) N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-
8-pentyloxy-1,2-dihydroquinoline-3-carboxamide.
``(CCCCC) N-[3-(2-methoxyethyl)-4,5-dimethylthiazol-2-
ylidene]-2,2,3,3-tetramethylcyclopropane-carboxamide.
``(DDDDD) 5-chloro-3-ethyl-N-[4-(piperidin-1-yl)phenethyl)-
1H-indole-2-carboximide.
``(EEEEE) N-[4-(dimethylamino)phenethyl]-3-ethyl-5-fluoro-
1H-indole-2-carboximide.
``(FFFFF) N-(1-benzylpyrrolidin-3-yl)-5-chloro-3-ethyl-1H-
indole-2-carboxamide.
``(GGGGG) [5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-
yl](naphthalene-1-yl)methanone.
``(HHHHH) (3'-(aminocarbonyl)[1,1'-biphenyl]-3-yl)-
cyclohexyl-carbamate.
``(IIIII) 5-(biphenyl-4-ylmethyl)-N,N-dimethyl-1H-
tetrazole-1-carboxamide.
``(JJJJJ) 6-methyl-2-(p-tolylamino)-4H-benzo[d][1,3]oxazin-
4-one.
``(KKKKK) [1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl
ester.
``(LLLLL) 4-hydroxy-N-(4-hydroxyphenethyl)-3-(pentylamino)-
benzamide.
``(MMMMM) 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl
cyclohexylcarbamate.
``(4) Arylcyclohexamines.--The substances listed in this paragraph
consist of the following arylcyclohexamines:
``(A) 1-(3-methoxyphenyl)-N-propylcyclohexan-amine.
``(B) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone.
``(C) 1-phenylcyclohexan-amine.
``(D) 1-[1-(benzothiophen-2-yl)cyclohexyl]piperidine.
``(E) 1-(1-p-tolylcyclohexyl)-piperidine.
``(F) 1-(4-methoxyphenyl)-N-propylcyclohexan-amine.
``(G) 1-[1-(4-methoxyphenyl)cyclohexyl]-piperidine.
``(H) 1-[1-(3-methoxyphenyl)cyclohexyl]-piperidine.
``(I) 1-phenyl-N-propylcyclohexanamine.
``(J) N-(2-methoxyethyl)-1-phenylcyclohexan-amine.
``(K) N-(2-ethoxyethyl)-1-phenylcyclohexan-amine.
``(L) N-(3-methoxypropyl)-1-phenylcyclohexan-amine.
``(M) 3-[1-(piperidin-1-yl)cyclohexyl]-phenol.
``(N) 2-(methoxyphenyl)-2-(methylamino)cyclohexanone.
``(O) N-ethyl-1-(thiophen-2-yl)cyclohexanamine.
``(P) (2-(2-chlorophenyl)-2-(ethylamino)-cyclohexanone).
``(5) Tryptamines.--The substances listed in this paragraph consist
of the following tryptamines:
``(A) 2-(1H-indol-3-yl)-N-methyl-ethanamine.
``(B) N-(2-(1H-indol-3-yl)ethyl-N-methylpropan-2-amine.
``(C) N-[2-(1H-indol-3-yl)ethyl]-N-isopropylpropan-2-amine.
``(D) N,N-dipropyl-1H-indole-3-ethanamine.
``(E) 3-[2-(diethylamino)ethyl]-1H-4yl acetate.
``(F) 3-(2-[isopropyl(methyl)amino]ethyl)-1H-indol-4-ol.
``(G) 3-[2-(bis[1-methylethyl]amino)ethyl]-1H-indol-4-ol
acetate.
``(H) 3-(2-[isopropyl(methyl)amino]ethyl)-1H-indol-4-ol
acetate.
``(I) 3-[2-(dimethylamino)ethyl]-1H-indol-4-yl acetate.
``(J) 4-hydroxy-N,N-diethyl-1H-indole-ethanamine.
``(K) 4-methoxy-N,N-dimethyl-1H-indole-3-ethanamine.
``(L) 3-(2-(diisopropylamino)ethyl)-1H-indol-4-ol.
``(M) 3-[2-(ethyl[methyl]amino)ethyl]-1H-indol-4-ol.
``(N) 3-[2-(ethyl[methyl]amino)ethyl]-1H-indol-4-yl
acetate.
``(O) 3-(2-(dipropylamino)ethyl)-1H-indol-4-ol.
``(P) 3-[2-(dipropylamino)ethyl]-1H-indol-4-yl acetate.
``(Q) 4-acetoxy-N,N-di-2-propen-1-yl-1H-indole-3-
ethanamine.
``(R) 5-methoxy-N,N-di-2-propen-1-yl-1H-indole-3-
ethanamine.
``(S) 3-(2-(dimethylaminoethyl)-1H-indol-5-ol.
``(T) 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine.
``(U) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropyl.
``(V) 1-(5-methoxy-1H-indol-3-yl)propan-2-amine.
``(W) 3-[2-(dimethylamino)-ethyl]-1H-indol-5-yl acetate.
``(X) N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propylpropan-
1-amine.
``(Y) N,N-diethyl-2-(5-methoxy-1H-indol-3-yl)ethanamine.
``(Z) N-ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methyl-
ethanamine.
``(6) Benzylpiperidines.--The substances listed in this paragraph
consist of the following benzylpiperidines:
``(A) 2-(diphenylmethyl)-piperidine.
``(B) 2-benzhydrylpyrrolidine.
``(C) a,a-diphenyl-(pyrrolidin-2-yl)methanol.
``(D) methyl 2-(3,4-dichlorophenyl)-2-(piperdin-2-
yl)acetate.
``(E) methyl 2-(3-chlorophenyl)-2-(piperidin-2-yl)acetate.
``(F) methyl 2-(piperidin-2-yl)-2-p-tolylacetate.
``(G) methyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate.
``(H) ethyl 2-phenyl-2-(piperidin-2-yl)acetate.
``(7) Benzodiazepines.--The substances listed in this paragraph
consist of the following benzodiazepines:
``(A) 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno-[3,2-
f][1,2,4]triazolo[4,3-a][1,4]diazepine.
``(B) 7-bromo-5-(2-chlorophenyl)-1H-benzo[e][1,4]diazepin-
2(3H)-one.
``(C) 8-bromo-1-methyl-6-phenyl-4H-
[1,2,4]triazolo[4,3a][1,4]benzodiazepine.
``(D) 3-methyl-6-[3-
(trifluoromethyl)phenyl][1,2,4]triazol[4,3-b]pyridazine.
``(E) 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-
pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate.
``(8) Opioids and Opioid-like Substances.--The substances listed in
this paragraph consist of the following opioids and opioid-like
substances:
``(A) 2-(1,3-dimethoxybuta-1,3-dien-2-yl)-3-ethyl-8-
methoxy-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quin olizine.
``(B) (2a,4aR,6aR,7R,9S,10aS10bR)-methyl-9-acetoxy-2-
(furan-3-yl)-6a,10b-dimethyl-4,10-dioxododecahydro-1 H-
benzo[f]isochromene-7-carboxylate.
``(C) 3,4-dichloro-N-([1-
(dimethylamino)cyclohexyl]methyl)benzamide.
``(D) 3-[2-(amino-1-methylethyl)-1-hydroxycyclohexyl]-
phenol.
``(E) 4,5-epoxy-17-methylmorphinan-3-ol.
``(F) N-phenyl-N-[1-(2-phenethyl)-4-piperidinyl] acetamide.
``(G) N-(1-benzylpiperidin-4-yl)-N-(x-fluorophenyl)-
butanamide.
``(H) 2-methyl-N-phenyl-N-[1-(1-phenylpropan-2-
yl)piperidin-4-yl]propanamide.
``(I) N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide.
``(J) 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine.
``(K) N-phenyl-N-(1-(2-(thiophen-2-yl)ethyl)piperidin-4-
yl)acetamide.
``(L) 4-chloro-N-(1-phenethylpiperidin-2-
ylidene)benzenesulfonamide.
``(M) 4-chloro-N-(1-(4-nitrophenethyl)piperidin-2-
ylidene)benzenesulfonamide.
``(9) Piperazines.--The substances listed in this paragraph consist
of the following piperazines:
``(A) 1,4-dibenzylpiperazine.
``(B) 1-(4-bromo-2,5-dimethoxybenzyl)-piperazine.
``(C) 1-(4-fluorophenyl)-piperazine.
``(D) 1-(2-methoxyphenyl)-piperazine.
``(E) 1-(4-chlorophenyl)-piperazine.
``(F) 1-(4-methoxyphenyl)-piperazine.
``(G) 1-(3-methylbenzyl)piperazine.
``(H) 1-benzyl-4-methylpiperazine.
``(10) Tropane Alkaloids.--The substances listed in this paragraph
consist of the following tropane alkaloids:
``(A) 8-methyl-8-azabicyclo[3.2.1]octan-3-yl 4-
fluorobenzoate.
``(B) methyl 3-(4-fluorophenyl)-8-methyl-8-
azabicyclo[3.2.1]octane-2-carboxylate.''.
(b) Effective Date.--The amendment made by subsection (a) takes
effect on the date that is 30 days after the date of enactment of this
Act.
<all>